Adjuvant treatment of adults with clear cell renal cell carcinoma (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions — in combination with belzutifan (Welireg)
FDA approved Keytruda (pembrolizumab, IV) and Keytruda Qlex (pembrolizumab + berahyaluronidase alfa-pmph, subcutaneous), each in combination with Welireg (belzutifan), for adjuvant treatment of adults with clear cell renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy. This is the first approved combination of a PD-1 inhibitor and a HIF-2α inhibitor.
